Clinical trials: Advanced Solid Malignant Tumor
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Solid Tumor, Adult
A Study of of HOT1030 in Patients With Advanced Solid Tumors
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030 in Patients with Advanced Solid Tumors
- Trial name
- NCT05060263
- Testing
- HOT-1030
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Advanced Solid Tumor, Breast Cancer
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
- Trial name
- NCT05251714
- Testing
- CFI-402257, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Treadwell Therapeutics, Inc
Advanced Solid Tumor
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer…
- Trial name
- NCT06938880
- Testing
- ZGGS18 for Injection, ZG005 for Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumor
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
- Trial name
- NCT06257680
- Testing
- ReT01 ACT
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Xunsheng Biomedical Research Co., Ltd.
Metastatic Solid Tumor
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2.
- Trial name
- TACTIC-3 (NCT05862324)
- Testing
- TAC01-CLDN18.2
- Where
- 9 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Triumvira Immunologics, Inc.
Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα)…
- Trial name
- NCT06804824
- Testing
- VVD-159642, Sotorasib, Trametinib
- Where
- 9 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Vividion Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced/Metastatic
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07641023)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung
- Trial name
- NCT04975256
- Testing
- MRTX849, BI 1701963
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation (Part 1) and dose-expansion (Part 2) first-in-human study in China to evaluate the safety, tolerability, PK profile and efficacy of GenSci140 in participants with…
- Trial name
- NCT07251166
- Testing
- GenSci140 for Injection
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Solid Tumor
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors. The study consisting of two lurbinectedin cycles, one cycle in combination with bosentan and one cycle as…
- Trial name
- NCT05072106
- Testing
- Lurbinectedin, Bosentan
- Where
- 2 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PharmaMar
Malignant Solid Tumor
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2).
- Trial name
- NCT03009214
- Testing
- AMC303
- Where
- 7 sites in Belgium, Spain
- Volunteers
- 55 people
- Sponsor
- amcure GmbH
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer
- Trial name
- ARC-12 (NCT04772989)
- Testing
- AB308, Zimberelimab
- Where
- 22 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Arcus Biosciences, Inc.
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer, Colorectal Cancer
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT06403735
- Testing
- QLC1101
- Where
- 5 sites in China
- Volunteers
- 250 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.